ECM
CBIO

Endurant Capital Management’s Crescent Biopharma CBIO Stock Holding History

Endurant Capital Management’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-423
Closed -$504K – 53
2019
Q2 		$504K Buy
+423
New +$506K 0.2% 48
2017
Q4 		– Sell
-176
Closed -$246K – 82
2017
Q3 		$246K Sell
176
-143
-45% -$168K 0.07% 85
2017
Q2 		$356K Buy
+319
New +$264K 0.1% 88
2017
Q1 		– Sell
-145
Closed -$88K – 92
2016
Q4 		$88K Buy
+145
New +$90.5K 0.04% 73

Other funds holding CBIO

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Axa
Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return

Endurant Capital Management's CBIO Position: Q3 2019 in Review

Endurant Capital Management sold out of Crescent Biopharma (CBIO) in Q3 2019, closing a stake of 423 shares — an estimated $504K sold.

Endurant Capital Management first reported a position in CBIO in Q4 2016 and held it in 4 quarters. The position peaked at $504K in Q2 2019. 75 funds tracked by Wall St. Rank hold CBIO as of Q3 2019.

  • Endurant Capital Management reported no remaining Crescent Biopharma position as of Q3 2019 after selling out during the quarter.
  • Endurant Capital Management sold 423 Crescent Biopharma shares in Q3 2019, an estimated $504K.
  • Endurant Capital Management first reported a position in Crescent Biopharma in Q4 2016 and held it in 4 quarters.
  • Endurant Capital Management's Crescent Biopharma position peaked at $504K in Q2 2019.
  • 75 funds tracked by Wall St. Rank held Crescent Biopharma as of Q3 2019.

Based on Endurant Capital Management's 13F filing for Q3 2019, filed 14 Nov 2019.